KLRG1

KLRG1

KLRG1 Molekülinformation

Molecule Name
Killer cell lectin-like receptor subfamily G member 1
Molekülalias
KLRG1
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
C-type lectin domain family 15 member A,ITIM-containing receptor MAFA-L,MAFA-like receptor,Mast cell function-associated antigen,CLEC15A,MAFA,MAFAL
Molekülhintergrund
The co-inhibitory receptor killer-cell lectin like receptor G1 (KLRG1) is specifically expressed on NK cells and activated CD8+ T-cells and has been postulated to be a marker of senescence. KLRG1+ T cells are a major reason of chronic tissue damage in some autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. In tumors, tumor cells which express E-cadherin or N-cadherin bind to KLRG1 and inhibit the antitumor activity of T and NK cells. Thus, KLRG1 acts as an immunocheckpoint inhibitory receptor.

KLRG1 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
UlviprubartABC008; ABC-008Phase 3 ClinicalAbcuro Inc
Leukemia, Large Granular Lymphocytic; Myositis, Inclusion Body
Details